Mankind Pharma
Mankind Pharma Limited, headquartered in New Delhi, India, is a prominent pharmaceutical company established in 1986 that focuses on the formulation, development, commercialization, and delivery of a wide array of pharmaceutical products. The company offers a diverse portfolio that includes antibiotics, antifungals, non-steroidal anti-inflammatory drugs (NSAIDs), gastrointestinal treatments, cardiovascular medications, and contraceptives, alongside over-the-counter medicines and nutritional supplements. Mankind Pharma also provides active pharmaceutical ingredients across various therapeutic areas such as cardiology, neurology, and gynecology. With a workforce exceeding 14,000, the company has built a strong presence in both the pharmaceutical and consumer healthcare sectors, catering primarily to the Indian market while also extending its reach to regions in Asia, Africa, Latin America, and the Gulf countries. Mankind Pharma is recognized for its well-established brands, including Manforce, Prega News, and Gas-O-Fast, and is committed to delivering affordable healthcare solutions to meet urgent medical needs.
Innov8 Coworking
Venture Round in 2025
Innov8 Coworking is a Y-Combinator backed startup based in India that offers premium workspaces, including managed private offices and coworking spaces. As the first of its kind in India, Innov8 Coworking creates a productive environment that fosters community engagement among diverse individuals such as founders, investors, freelancers, and creators. The company currently operates multiple centers across major cities in India, including Delhi, Noida, Gurgaon, Mumbai, Bangalore, and Chandigarh. Innov8 Coworking provides essential amenities such as high-speed internet, meeting and conference rooms, and complimentary beverages, all aimed at facilitating collaboration and idea sharing among startup businesses.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.